ASH 2023 | Low bone marrow cellularity predicts hematologic AEs to CPX-351 in AML
Fabio Guolo
• 10 Dec 2023
Fabio Guolo, MD, University of Genoa, Genoa, Italy, discusses predictors of prolonged hematologic adverse events (AEs) to CPX-351 treatment in patients with acute myeloid leukemia (AML). A low bone marrow cellularity at diagnosis correlates with an increased risk for prolonged AEs, such as cytopenia, although this does not impact treatment outcomes for these patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
